RTP Mobile Logo
Select Publications

Andre T et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. ASCO 2020;Abstract LBA4.

Antoniotti C et al. Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study. ASCO 2020;Abstract 4077.

Cousin S et al. REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort. ASCO 2020;Abstract 4019.

Coutzac C et al. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study. ASCO 2020;Abstract 4036.

Deming DA et al. Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). ASCO 2020;Abstract 4046.

Diaz LA et al. Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study. ASCO 2020;Abstract 4032.

Eng C. TAS-102 plus bevacizumab: A new standard for metastatic colorectal cancer? Lancet Oncol 2020;21(3):326-7. Abstract

Fukuoka S et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38(18):2053-61. Abstract

Kopetz S et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). ASCO 2020;Abstract 4001.

Kopetz S et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). ASCO 2020;Abstract 4039.

Kopetz S et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381(17):1632-43. Abstract

Lenz HJ et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. ASCO 2020;Abstract 4040.

Lonardi S et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. ASCO 2020;Abstract 4002.

Ogata M et al. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. PLoS One 2020;15(6):e0234314. Abstract

Pfeiffer P et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(3):412-20. Abstract

Siena S et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. ASCO 2020;Abstract 4000.

Su GL et al. A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. J Int Med Res 2020;48(7):300060520926408. Abstract

Unseld M et al. Different toxicity profiles predict third line treatment efficacy in metastatic colorectal cancer patients. J Clin Med 2020;9(6):E1772. Abstract

Vivolo R et al. Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts). ASCO 2020;Abstract 4082.

Zakka KM et al. Impact of tumor side on clinical outcomes in stage II and III colon cancer with known microsatellite instability status. ASCO 2020;Abstract 4068.